Daniel Kirouac - Scientist, PTPK (Pre-clinical & Translational Pharmacokinetics)/Quantitative Systems Pharmacology

Daniel Kirouac

Scientist, PTPK (Pre-clinical & Translational Pharmacokinetics)/Quantitative Systems Pharmacology

"Working at Genentech allows one the opportunity to push the boundaries of science, and then see the fruits of discovery be directed toward the benefit of patients."
2
Years at Genentech
7
Awards & Honors

I joined Genentech as a Scientist in 2015, part of a new Quantitative & Systems Pharmacology group. Our aim is to build computational models of disease at the cellular level, and use these models to explore, via simulations, how to better design, develop, and use new medicines to treat disease. We thus borrow approaches from engineering, mathematics, and computer science to address pressing medical problems.

My background is in chemical engineering – I have a PhD from the University of Toronto, and before moving to California did a post-doc at MIT, and worked in the Boston-area biotech industry. Working at Genentech allows me the opportunity to push the boundaries of science, and then see the fruits of discovery be directed toward the benefit of patients.

Featured Publication

A Six-Stage Workflow for Robust Application of Systems Pharmacology.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):235-49.

Gadkar K, Kirouac DC, Mager DE, van der Graaf PH, Ramanujan S.

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.

PLoS Comput Biol. 2016 Apr 1;12(4):e1004827.

Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF.